Pfizer and Allergan considering a merger
29 October 2015 | By Victoria White
Allergan has said that it is in preliminary “friendly discussions” with Pfizer regarding a potential business combination transaction...
List view / Grid view
News
FDA approves Yervoy as adjuvant treatment for stage III melanoma
29 October 2015 | By Victoria White
This approval is based on clinical data from a pivotal Phase 3 trial which demonstrated Yervoy significantly improved recurrence-free survival vs. placebo in this setting...
Landmark clinical trial shows olaparib can treat prostate cancer
29 October 2015 | By Victoria White
The trial is a milestone in cancer treatment as the first to show the benefits of ‘precision medicine’ in prostate cancer...
World Stroke Day: Daiichi Sankyo highlights stroke risks associated with cardiovascular diseases
29 October 2015 | By Victoria White
To mark its support for World Stroke Day, Daiichi Sankyo has initiated a campaign that highlights stroke risks associated with cardiovascular diseases...
NICE recommends tolvaptan for patients with ADPKD
28 October 2015 | By Victoria White
Tolavptan is the first-ever treatment shown to slow progression of the life-threatening condition...
Boehringer Ingelheim announces data for Spiolto Respimat and biosimilar candidate
28 October 2015 | By Victoria White
Boehringer Ingelheim today announced new data from post-hoc analyses of studies of Spiolto Respimat and a Phase I trial of its adalimumab biosimilar candidate...
First patient dosed in Phase 3 trial of gilteritinib in AML
28 October 2015 | By Victoria White
Gilteritinib has demonstrated inhibitory activity against FLT3 internal tandem duplication as well as tyrosine kinase domain, two common types of FLT3 mutations that are seen in AML...
GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles
28 October 2015 | By Kate Douetil
GSK’s candidate shingles vaccine is a non-live vaccine and combines gE, a protein found on the virus that causes shingles with an adjuvant system, AS01B, which enhances the immunological response to gE...
FDA approves Imlygic for the treatment of melanoma lesions
28 October 2015 | By Victoria White
Imylgic is a genetically modified herpes simplex virus type 1 designed to replicate within tumours and produce an immunostimulatory protein called GM-CSF...
No difference in efficacy or immunogenicity following switch to biosimilar Remsima
28 October 2015 | By Victoria White
New clinical data indicate no differences in efficacy, adverse events and immunogenicity when patients with inflammatory bowel disease are switched to biosimilar infliximab Remsima from originator infliximab...
Phase 3 trial of Adcetris in Hodgkin lymphoma completes target enrolment
27 October 2015 | By Victoria White
Data from a Phase 1 trial evaluating Adcetris plus AVD demonstrated that 24 of 25 patients (96 percent) achieved a complete remission...
Donepezil may delay residential care for Alzheimer’s sufferers
27 October 2015 | By Victoria White
Withdrawing donepezil from people in the advanced stages of Alzheimer's disease doubles their risk of being placed in a nursing home within a year, according to a UCL study...
GSK’s losmapimod cardiovascular study fails
27 October 2015 | By Victoria White
An interim review of data from part A of the Phase III study did not indicate efficacy against the primary endpoint and did not support investment in the larger part B of the study...
First patient enrolled in Phase 2 study of Onivyde in pancreatic adenocarcinoma
27 October 2015 | By Victoria White
The start-up of this study resulted in $62.5M of milestone payments to Merrimack from Baxalta...
Positive results for Shire’s lifitegrast in dry eye disease
27 October 2015 | By Victoria White
A Phase 3 trial of lifitegrast met its primary endpoint of significantly improving patient-reported symptoms of dry eye disease from baseline to day 84...
